WallStreetZenWallStreetZen

NASDAQ: CHRS
Coherus Oncology Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Coherus Oncology earnings were $155.0M for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. The latest CHRS earnings report on Sep 30, 2025 announced Q3 2025 earnings of -$35.5M, down 111.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CHRS reported annual earnings of $28.5M, with -112% growth. The next CHRS earnings date is Mar 17, 2026.

CHRS past earnings growth

How has CHRS's earnings growth performed historically?

Company
N/A
Industry
59.6%
Market
54.41%
CHRS's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
CHRS's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

CHRS earnings history

Current Revenue
$83.6M
Current Earnings
$155.0M
Current Profit Margin
185.4%

CHRS Return on Equity

Current Company
-574.7%
Current Industry
-21.2%
Current Market
35.1%
CHRS's Return on Equity (-574.7%)... subscribe to Premium to read more.
High Return on Equity Performance

CHRS Return on Assets

Current Company
34.9%
Current Industry
-8.8%
CHRS is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when CHRS announces earnings.

CHRS Return on Capital Employed

Current Company
115.84%
Current Industry
-3.5%
CHRS has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CHRS vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
CHRS$172.52M$154.97M-10.22%$1.33
TARA-$52.55M-$52.90MN/A-$1.38
HRTX-$8.74M-$13.58MN/A-$0.08
NAUT-$56.38M-$62.81MN/A-$0.50
STTK-$50.69M-$54.90MN/A-$1.02
View Top Biotech Stocks

CHRS earnings dates

Next earnings date
Mar 17, 2026

Coherus Oncology Earnings Reports & History FAQ

What were Coherus Oncology's earnings last quarter?

On CHRS's earnings call on Invalid Date, Coherus Oncology (NASDAQ: CHRS) reported Q3 2025 earnings per share (EPS) of -$0.31, up 244.44% year over year. Total CHRS earnings for the quarter were -$35.53 million. In the same quarter last year, Coherus Oncology's earnings per share (EPS) was -$0.09.

If you're new to stock investing, here's how to buy Coherus Oncology stock.

When does Coherus Oncology report earnings?

The next CHRS earnings call is Invalid Date. Add CHRS to your watchlist to be reminded of Coherus Oncology's next earnings date.

Is Coherus Oncology profitable or losing money?

As of the last Coherus Oncology earnings report, Coherus Oncology is currently profitable. Coherus Oncology's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $154.97 million, a 34,538% decrease year over year.

What was CHRS's earnings growth in the past year?

As of Coherus Oncology's earnings date in Invalid Date, Coherus Oncology's earnings has grown year over year. CHRS earnings in the past year totalled $154.97 million.

What are Coherus Oncology's earnings expectations?

The current EPS estimate for Coherus Oncology's earnings report in Invalid Date is -$0.34.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.